What factors are considered when evaluating a treatment or prophylaxis limitation in Step 2A Prong Two?
According to MPEP 2106.04(d)(2), there are three main factors to consider when evaluating a treatment or prophylaxis limitation in Step 2A Prong Two: The particularity or generality of the treatment or prophylaxis: The limitation must be “particular,” i.e., specifically identified so that it does not encompass all applications of the judicial exception(s). Whether the limitation(s)…
Read MoreWhat factors are considered when evaluating a declaration under 37 CFR 1.130(b)?
When evaluating a declaration under 37 CFR 1.130(b), the USPTO considers several factors: Whether the disclosure is subject to the exceptions of 35 U.S.C. 102(b)(1)(B) or 102(b)(2)(B) Whether the affidavit shows sufficient facts to establish that the subject matter was publicly disclosed by the inventor or someone who obtained it from the inventor Whether the…
Read More